[1]张建东,贺利民,马　磊,等.表皮生长因子受体基因突变和切除修复交叉互补蛋白1蛋白表达与肺腺癌患者临床病理特征及预后的关系[J].新乡医学院学报,2016,33(10):894-897.[doi:10.7683/xxyxyxb.2016.10.015]
　ZHANG Jian-dong,HE Li-min,MA Lei,et al.Relation of expression of epidermal growth factor receptor genic mutation&excision repair cross complementing protein1 with clinicopathological features&prognosis in pulmonary adenocarcinoma patients[J].Journal of Xinxiang Medical University,2016,33(10):894-897.[doi:10.7683/xxyxyxb.2016.10.015]
点击复制

表皮生长因子受体基因突变和切除修复交叉互补蛋白1蛋白表达与肺腺癌患者临床病理特征及预后的关系
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年10
页码:
894-897
栏目:
临床研究
出版日期:
2016-10-05

文章信息/Info

Title:
Relation of expression of epidermal growth factor receptor genic mutation&excision repair cross complementing protein1 with clinicopathological features&prognosis in pulmonary adenocarcinoma patients
作者:
张建东1; 贺利民2; 马　磊2; 张　振2; 姚传山2; 尤　朵3; 闻朋浩4
(1.新乡医学院，河南　新乡　453003；2.南阳市第一人民医院肿瘤科，河南　南阳　473012；3.新乡医学院第一附属医院肿瘤科，河南　卫辉　453100；4.河南大学附属南石医院肿瘤科，河南　南阳　473065)
Author(s):
ZHANG Jian-dong1; HE Li-min2; MA Lei2; ZHANG Zhen2; YAO Chuan-shan2; YOU Duo3; WEN Peng-hao4
（1.Xinxiang Medical University,Xinxiang 453003，Henan Province,China；2.Department of Oncology，the First People′s Hospital of Nanyang City，Nanyang 473012，Henan Province,China；3.Department of Oncology，the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100，Henan Province,China；4.Department of Oncology，Nanshi Hospital Affiliated to Henan University，Nanyang 473065，Henan Province，China）
关键词:
肺腺癌; 表皮生长因子受体; 突变; 切除修复交叉互补蛋白1; 临床病理特征; 预后
Keywords:
pulmonary adenocarcinoma; epidermal growth factor receptor; mutation; excision repair cross complementing protein 1; clinical pathological characteristics; prognosis
分类号:
R734.2
DOI:
10.7683/xxyxyxb.2016.10.015
文献标志码:
A
摘要:
目的　探讨表皮生长因子受体（EGFR）基因突变和切除修复交叉互补蛋白1（ERCC1）蛋白表达与肺腺癌患者临床病理特征及预后的关系。方法　收集2010年3月至2011年6月在南阳市第一人民医院及新乡医学院第一附属医院手术治疗的160例肺腺癌患者的肺腺癌组织标本，应用扩增阻滞突变系统在荧光定量聚合酶链反应仪上检测EGFR基因19及21外显子突变情况，同时采用免疫组织化学法检测组织中ERCC1蛋白表达，分析EGFR基因突变、ERCC1蛋白表达与肺腺癌患者临床病理特征及预后的关系。结果　EGFR基因突变在女性、无吸烟史、肿瘤直径<5 cm患者中较高（P<0.05），而与肺腺癌患者的年龄、病理分期及淋巴结转移情况无关（P>0.05）；ERCC1蛋白表达与病理分期有关（P<0.05），与患者的性别、年龄、是否吸烟、肿瘤直径及淋巴结转移无关（P>0.05）。EGFR基因发生突变的肺腺癌病理组织中ERCC1蛋白低表达者多，EGFR基因未发生突变的肺腺癌病理组织中ERCC1低表达较少，二者比较差异有统计学意义(χ2=7.253，P<0.01)。EGFR突变阳性患者的无进展生存期（PFS）长于EGFR突变阴性患者（χ2=9.567，P<0.01）；ERCC1蛋白低表达患者的PFS长于ERCC1蛋白高表达患者（χ2=10.025，P<0.01）。结论　肺腺癌EGFR突变者ERCC1蛋白倾向于低表达，存在EGFR基因突变或者ERCC1蛋白低表达的患者PFS更长。
Abstract:
Objective　To study the relationship of expression of epidermal growth factor receptor（EGFR） genic mutation and excision repair cross complementing protein 1 （ERCC1）with clinicopathological features and prognosis in pulmonary adenocarcinoma patients.Methods　The sample of pulmonary adenocarcinoma tissue in 160 cases with pulmonary adenocarcinoma were collected in the First People′s Hospital of Nanyang City and the First Affiliated Hospital of Xinxiang Medical University from March 2010 to June 2011.Mutation of 19 and 21 exon of EGFR gene was detected by amplification refractory system in fluorescence quantitative polymerase chain reaction,while the expression of ERCC1 protein in tissue was determined by immunohistochemistry.The relationship of EGFR genic mutation and expression of ERCC1 with clinical pathological features and prognosis was analysed.Results　EGFR genic mutation in female patients,and no smoking history of patients,tumor diameter less than 5 cm was higher (P<0.05),and it had no connection with lung adenocarcinoma patients with age,pathological staging and lymph node transfer(P>0.05).ERCC1 protein expression concerned with pathological stage (P<0.05),but it had no connection with with the patient′s gender,age,smoking,tumor diameter and lymph node transfer (P>0.05).Expression of ERCC1 protein in lung adenocarcinoma with EGFR genic mutation was low,EGFR low expression of ERCC1 in lung adenocarcinoma with no mutation of the gene was low,the difference was statistically significant between the two groups (χ2=7.253,P<0.01).The progression free survival (PFS) of EGFR genic mutation positive patients was longer than that of EGFR genic mutation negative patients (χ2=9.567,P<0.01);the PFS of patients with low expression of ERCC1 protein was longer than that of high expression of ERCC1 protein (χ2=10.025,P<0.01).Conclusion　The expression of ERCC1 protein in pulmonary adenocarcinoma patients with EGFR genic mutation is low.The PFS of pulmonary adenocarcinoma patients with EGFR genic mutantion or low expression of ERCC1 protein is longer.

参考文献/References:

［1］　JEMAL A，SIEGEL R，XU J，et al.Cancer statistics，2010［J］.CA Cancer J Clin，2010，60(5)：277-300.
［2］　MITSUDOMI T，MORITA S，YATABE Y，et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label,randomised phase 3 trial［J］.Lancet Oncol，2010，11(2)：121-128.
［3］　CHAN S K，GULLICK W J，HILL M E.Mutations of the epidermal growth factor receptor in non small cell lung cancer：search and destroy［J］.Eur J Cancer，2006，42(1)：17-23.
［4］　ZHOU C，WU Y L，CHEN G，et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):a multicentre,open-label,randomised,phase 3 study［J］.Lancet Oncol，2011，12(8)：735-742.
［5］　MOK T S，WU Y L，THONGPRASERT S，et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma［J］.N Engl J Med，2009，361(10)：947-957.
［6］　PARK J H，LEE S H，KEAM B，et al.EGFR mutations as a predictive marker of cytotoxic chemotherapy［J］.Lung Cancer，2012，77(2)：433-437.
［7］　KALIKAKI A，KOUTSOPOULOS A，HATZIDAKI D，et al.Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status［J］.Lung Cancer，2010，69(1)：110-115.
［8］　BESSE B，OLAUSSEN K A，SORIA J C.ERCC1 and RRM1:ready for prime time［J］.J Clin Oncol，2013，31(8)：1050-1060.
［9］　AZUMA K，SASA T，KAWAHARA A，et al.Expression of ERCC1 and class Ⅲ beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel［J］.Lung Cancer，2009，64(3)：326-333.
［10］　GANDARA D R，GRIMMINGER P，MACK P C，et al.Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer［J］.J Thorac Oncol，2010，5(12)：1933-1938.
［11］　任睿欣，李嘉瑜，李雪飞，等.扩增阻滞突变系统法检测非小细胞肺癌微小标本表皮生长因子受体突变［J］.肿瘤，2012，32(11)：929-935.
［12］　REN S，CHEN X，KUANG P，et al.Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma［J］.Cancer，2012，118(22)：5588-5594.
［13］　LEE K H，MIN H S，HAN S W，et al.ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer［J］.Lung Cancer，2008，60(3)：401-407.
［14］　KOSAKA T，YATABE Y，Endoh H，et al.Mutations of the epidermal growth factor receptor gene in lung cancer:biological and clinical implications［J］.Cancer Res，2004，64(24)：8919-8923.
［15］　KAWAHARA A，AZUMA K，HATTORI S，et al.The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer［J］.Human Pathology，2010，41(7)：951-959.
［16］　HUBENER R A，RILEY R D，BILLINGHAM L J，et al.Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes:a meta-analysis of published studies and recommendations［J］.PLoS One，2011，6(10)：e25164.

相似文献/References:

[1]蔡新华,张钦宪,唐亮,等.表皮生长因子受体靶向重组T7噬菌体抗肿瘤疫苗的免疫活性[J].新乡医学院学报,2005,22(03):188.
[2]曹名波,邹百仓,秦　斌.荆花胃康胶丸对实验性胃溃疡大鼠粘膜愈合和EGF、EGFR表达的影响[J].新乡医学院学报,2006,23(05):478.
[3]申龙树,谢 玲,陈 劼,等.肺腺癌表皮生长因子受体基因突变及临床意义[J].新乡医学院学报,2014,31(10):796.[doi:10.7683/xxyxyxb.2014.10.007]
[4]杨艳荣.培美曲塞与吉西他滨联合顺铂治疗晚期肺腺癌疗效及安全性比较[J].新乡医学院学报,2015,32(12):1103.
[5]范改焕,禹香菊,赵宪文.肺炎支原体对支气管上皮细胞黏蛋白分泌的影响[J].新乡医学院学报,2018,35(11):975.[doi:10.7683/xxyxyxb.2018.11.007]
　FAN Gai-huan,YU Xiang-ju,ZHAO Xian-wen.Effect of Mycoplasma pneumoniae on the mucin secretion in bronchial epithelial cells[J].Journal of Xinxiang Medical University,2018,35(10):975.[doi:10.7683/xxyxyxb.2018.11.007]
[6]杨成轩,贾　良,孙艳霞,等.共刺激因子B7同源体4在肺腺癌组织中的表达及临床意义[J].新乡医学院学报,2019,36(9):833.[doi:10.7683/xxyxyxb.2019.09.007]
　YANG Cheng-xuan,JIA Liang,SUN Yan-xia,et al.Expression of costimulate molecules B7 homolog 4 in lung adenocarcinoma tissues and its clinical significance[J].Journal of Xinxiang Medical University,2019,36(10):833.[doi:10.7683/xxyxyxb.2019.09.007]
[7]秦　 超,冯永海,杨闪闪,等.结肠癌转移相关基因1表达与肺鳞状细胞癌和肺腺癌细胞顺铂耐药性的相关性[J].新乡医学院学报,2021,38(3):249.[doi:10.7683/xxyxyxb.2021.03.009]
　QIN Chao,FENG Yonghai,YANG Shanshan,et al.Relationship between the expression of metastasis-associated in colon cancer 1 and cisplatin resistance in pulmonary squamous cell carcinoma and pulmonary adenocarcinoma cells[J].Journal of Xinxiang Medical University,2021,38(10):249.[doi:10.7683/xxyxyxb.2021.03.009]
[8]李晓亮,杨志刚,马希涛,等.中分化肺腺癌及癌旁组织中差异蛋白质组学分析[J].新乡医学院学报,2019,36(4):315.[doi:10.7683/xxyxyxb.2019.04.004]
　LI Xiao-liang,YANG Zhi-gang,MA Xi-tao,et al.Differential proteomic analysis of human moderately differentiated lung adenocarcinoma and adjacent tissues[J].Journal of Xinxiang Medical University,2019,36(10):315.[doi:10.7683/xxyxyxb.2019.04.004]
[9]姜碧杰,刘　扬,李聪敏,等.膜受体在空气污染致健康损害过程中的作用[J].新乡医学院学报,2018,35(2):088.[doi:10.7683/xxyxyxb.2018.02.002]
　N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(10):088.[doi:10.7683/xxyxyxb.2018.02.002]
[10]刘　勇,徐天娇,霍金莲.Ku70乙酰化在硒诱导人肺腺癌A549细胞凋亡中的作用[J].新乡医学院学报,2017,34(2):099.[doi:10.7683/xxyxyxb.2017.02.005]
　LIU Yong,XU Tian-jiao,HUO Jin-lian.Effect of Ku70 acetylation on selenium-induced apoptosis of human pulmonary adenocarcinoma A549 cell[J].Journal of Xinxiang Medical University,2017,34(10):099.[doi:10.7683/xxyxyxb.2017.02.005]
[11]贾　瑞,薛　雷,杜海荣,等.冀东满族肺腺癌患者表皮生长因子受体基因突变分析[J].新乡医学院学报,2015,32(05):408.

更新日期/Last Update: 2016-10-05